Skip to main content
NCBI home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1996 May;34(5):1058–1064. doi: 10.1128/jcm.34.5.1058-1064.1996

Comparative evaluation of NASBA HIV-1 RNA QT, AMPLICOR-HIV monitor, and QUANTIPLEX HIV RNA assay, three methods for quantification of human immunodeficiency virus type 1 RNA in plasma.

H Revets 1, D Marissens 1, S de Wit 1, P Lacor 1, N Clumeck 1, S Lauwers 1, G Zissis 1
PMCID: PMC228954  PMID: 8727875

Abstract

Three commercial assays for quantifying plasma human immunodeficiency virus type 1 (HIV-1) RNA were evaluated. The assays differed in their sample volumes, the means of preparing samples, and methods of amplification and detection. Plasma samples were obtained from 36 HIV-1-infected patients representing all stages of HIV-1 infection and were analyzed as coded specimens. Measurement of HIV-1 RNA baseline levels revealed no significant difference in sensitivity between the three assays. The assays were also applied to the quantitation of HIV-1 RNA levels in the plasma of patients who were changing their antiretroviral therapy. The changes measured in HIV-1 RNA levels in plasma in response to therapy were comparable by the three assays. No close correlation was found between the amount of HIV-1 RNA and the CD4 T-cell count; HIV-1 RNA assays were more sensitive than p24 antigen assays as an indicator of plasma viremia. Overall, the study demonstrates that all three quantitative assays for HIV-1 RNA can be used to measure the HIV-1 RNA copy number representing the HIV-1 viremia status in patients with HIV-1 infection. Since this copy number is likely to be useful in monitoring the effectiveness of antiviral therapy, these quantitative assays for HIV-1 RNA are ready to be built into clinical trials.

Full Text

The Full Text of this article is available as a PDF (230.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aboulker J. P., Swart A. M. Preliminary analysis of the Concorde trial. Concorde Coordinating Committee. Lancet. 1993 Apr 3;341(8849):889–890. doi: 10.1016/0140-6736(93)93096-j. [DOI] [PubMed] [Google Scholar]
  2. Allain J. P., Laurian Y., Paul D. A., Senn D. Serological markers in early stages of human immunodeficiency virus infection in haemophiliacs. Lancet. 1986 Nov 29;2(8518):1233–1236. doi: 10.1016/s0140-6736(86)92673-5. [DOI] [PubMed] [Google Scholar]
  3. Bagnarelli P., Menzo S., Valenza A., Paolucci S., Petroni S., Scalise G., Sampaolesi R., Manzin A., Varaldo P. E., Clementi M. Quantitative molecular monitoring of human immunodeficiency virus type 1 activity during therapy with specific antiretroviral compounds. J Clin Microbiol. 1995 Jan;33(1):16–23. doi: 10.1128/jcm.33.1.16-23.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Boom R., Sol C. J., Salimans M. M., Jansen C. L., Wertheim-van Dillen P. M., van der Noordaa J. Rapid and simple method for purification of nucleic acids. J Clin Microbiol. 1990 Mar;28(3):495–503. doi: 10.1128/jcm.28.3.495-503.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Compton J. Nucleic acid sequence-based amplification. Nature. 1991 Mar 7;350(6313):91–92. doi: 10.1038/350091a0. [DOI] [PubMed] [Google Scholar]
  6. Coombs R. W., Collier A. C., Allain J. P., Nikora B., Leuther M., Gjerset G. F., Corey L. Plasma viremia in human immunodeficiency virus infection. N Engl J Med. 1989 Dec 14;321(24):1626–1631. doi: 10.1056/NEJM198912143212402. [DOI] [PubMed] [Google Scholar]
  7. Dewar R. L., Highbarger H. C., Sarmiento M. D., Todd J. A., Vasudevachari M. B., Davey R. T., Jr, Kovacs J. A., Salzman N. P., Lane H. C., Urdea M. S. Application of branched DNA signal amplification to monitor human immunodeficiency virus type 1 burden in human plasma. J Infect Dis. 1994 Nov;170(5):1172–1179. doi: 10.1093/infdis/170.5.1172. [DOI] [PubMed] [Google Scholar]
  8. Goudsmit J., de Wolf F., Paul D. A., Epstein L. G., Lange J. M., Krone W. J., Speelman H., Wolters E. C., Van der Noordaa J., Oleske J. M. Expression of human immunodeficiency virus antigen (HIV-Ag) in serum and cerebrospinal fluid during acute and chronic infection. Lancet. 1986 Jul 26;2(8500):177–180. doi: 10.1016/s0140-6736(86)92485-2. [DOI] [PubMed] [Google Scholar]
  9. Ho D. D., Moudgil T., Alam M. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med. 1989 Dec 14;321(24):1621–1625. doi: 10.1056/NEJM198912143212401. [DOI] [PubMed] [Google Scholar]
  10. Ho D. D., Neumann A. U., Perelson A. S., Chen W., Leonard J. M., Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995 Jan 12;373(6510):123–126. doi: 10.1038/373123a0. [DOI] [PubMed] [Google Scholar]
  11. Holodniy M., Katzenstein D. A., Israelski D. M., Merigan T. C. Reduction in plasma human immunodeficiency virus ribonucleic acid after dideoxynucleoside therapy as determined by the polymerase chain reaction. J Clin Invest. 1991 Nov;88(5):1755–1759. doi: 10.1172/JCI115494. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Holodniy M., Katzenstein D. A., Sengupta S., Wang A. M., Casipit C., Schwartz D. H., Konrad M., Groves E., Merigan T. C. Detection and quantification of human immunodeficiency virus RNA in patient serum by use of the polymerase chain reaction. J Infect Dis. 1991 Apr;163(4):862–866. doi: 10.1093/infdis/163.4.862. [DOI] [PubMed] [Google Scholar]
  13. Holodniy M., Katzenstein D., Winters M., Montoya J., Shafer R., Kozal M., Ragni M., Merigan T. C. Measurement of HIV virus load and genotypic resistance by gene amplification in asymptomatic subjects treated with combination therapy. J Acquir Immune Defic Syndr. 1993 Apr;6(4):366–369. [PubMed] [Google Scholar]
  14. Horn T., Urdea M. S. Forks and combs and DNA: the synthesis of branched oligodeoxyribonucleotides. Nucleic Acids Res. 1989 Sep 12;17(17):6959–6967. doi: 10.1093/nar/17.17.6959. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Katzenstein D. A., Holodniy M., Israelski D. M., Sengupta S., Mole L. A., Bubp J. L., Merigan T. C. Plasma viremia in human immunodeficiency virus infection: relationship to stage of disease and antiviral treatment. J Acquir Immune Defic Syndr. 1992;5(2):107–112. [PubMed] [Google Scholar]
  16. Kievits T., van Gemen B., van Strijp D., Schukkink R., Dircks M., Adriaanse H., Malek L., Sooknanan R., Lens P. NASBA isothermal enzymatic in vitro nucleic acid amplification optimized for the diagnosis of HIV-1 infection. J Virol Methods. 1991 Dec;35(3):273–286. doi: 10.1016/0166-0934(91)90069-c. [DOI] [PubMed] [Google Scholar]
  17. Kojima E., Shirasaka T., Anderson B., Chokekijchai S., Sei S., Yarchoan R., Mitsuya H. Monitoring the activity of antiviral therapy for HIV infection using a polymerase chain reaction method coupled with reverse transcription. AIDS. 1993 Nov;7 (Suppl 2):S101–S105. doi: 10.1097/00002030-199311002-00019. [DOI] [PubMed] [Google Scholar]
  18. Koot M., Vos A. H., Keet R. P., de Goede R. E., Dercksen M. W., Terpstra F. G., Coutinho R. A., Miedema F., Tersmette M. HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay. AIDS. 1992 Jan;6(1):49–54. doi: 10.1097/00002030-199201000-00006. [DOI] [PubMed] [Google Scholar]
  19. Lange J. M., Paul D. A., Huisman H. G., de Wolf F., van den Berg H., Coutinho R. A., Danner S. A., van der Noordaa J., Goudsmit J. Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS. Br Med J (Clin Res Ed) 1986 Dec 6;293(6560):1459–1462. doi: 10.1136/bmj.293.6560.1459. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Lelie P. N., Reesink H. W., Bakker E., Huisman J. G., ten Veen J. H. Clinical importance of HIV antigen and anti-HIV core markers in persons infected with HIV. N Engl J Med. 1988 May 5;318(18):1204–1205. doi: 10.1056/NEJM198805053181814. [DOI] [PubMed] [Google Scholar]
  21. Lin H. J., Myers L. E., Yen-Lieberman B., Hollinger F. B., Henrard D., Hooper C. J., Kokka R., Kwok S., Rasheed S., Vahey M. Multicenter evaluation of quantification methods for plasma human immunodeficiency virus type 1 RNA. J Infect Dis. 1994 Sep;170(3):553–562. doi: 10.1093/infdis/170.3.553. [DOI] [PubMed] [Google Scholar]
  22. Longo M. C., Berninger M. S., Hartley J. L. Use of uracil DNA glycosylase to control carry-over contamination in polymerase chain reactions. Gene. 1990 Sep 1;93(1):125–128. doi: 10.1016/0378-1119(90)90145-h. [DOI] [PubMed] [Google Scholar]
  23. Loveday C., Kaye S., Tenant-Flowers M., Semple M., Ayliffe U., Weller I. V., Tedder R. S. HIV-1 RNA serum-load and resistant viral genotypes during early zidovudine therapy. Lancet. 1995 Apr 1;345(8953):820–824. doi: 10.1016/s0140-6736(95)92963-0. [DOI] [PubMed] [Google Scholar]
  24. Lu W., Andrieu J. M. Early identification of human immunodeficiency virus-infected asymptomatic subjects susceptible to zidovudine by quantitative viral coculture and reverse transcription-linked polymerase chain reaction. J Infect Dis. 1993 May;167(5):1014–1020. doi: 10.1093/infdis/167.5.1014. [DOI] [PubMed] [Google Scholar]
  25. Mulder J., McKinney N., Christopherson C., Sninsky J., Greenfield L., Kwok S. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol. 1994 Feb;32(2):292–300. doi: 10.1128/jcm.32.2.292-300.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Myers T. W., Gelfand D. H. Reverse transcription and DNA amplification by a Thermus thermophilus DNA polymerase. Biochemistry. 1991 Aug 6;30(31):7661–7666. doi: 10.1021/bi00245a001. [DOI] [PubMed] [Google Scholar]
  27. Nishanian P., Huskins K. R., Stehn S., Detels R., Fahey J. L. A simple method for improved assay demonstrates that HIV p24 antigen is present as immune complexes in most sera from HIV-infected individuals. J Infect Dis. 1990 Jul;162(1):21–28. doi: 10.1093/infdis/162.1.21. [DOI] [PubMed] [Google Scholar]
  28. Pachl C., Todd J. A., Kern D. G., Sheridan P. J., Fong S. J., Stempien M., Hoo B., Besemer D., Yeghiazarian T., Irvine B. Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Apr 15;8(5):446–454. doi: 10.1097/00042560-199504120-00003. [DOI] [PubMed] [Google Scholar]
  29. Pan L. Z., Werner A., Levy J. A. Detection of plasma viremia in human immunodeficiency virus-infected individuals at all clinical stages. J Clin Microbiol. 1993 Feb;31(2):283–288. doi: 10.1128/jcm.31.2.283-288.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Paul D. A., Falk L. A., Kessler H. A., Chase R. M., Blaauw B., Chudwin D. S., Landay A. L. Correlation of serum HIV antigen and antibody with clinical status in HIV-infected patients. J Med Virol. 1987 Aug;22(4):357–363. doi: 10.1002/jmv.1890220408. [DOI] [PubMed] [Google Scholar]
  31. Phillips A. N., Lee C. A., Elford J., Janossy G., Timms A., Bofill M., Kernoff P. B. Serial CD4 lymphocyte counts and development of AIDS. Lancet. 1991 Feb 16;337(8738):389–392. doi: 10.1016/0140-6736(91)91166-r. [DOI] [PubMed] [Google Scholar]
  32. Piatak M., Jr, Saag M. S., Yang L. C., Clark S. J., Kappes J. C., Luk K. C., Hahn B. H., Shaw G. M., Lifson J. D. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science. 1993 Mar 19;259(5102):1749–1754. doi: 10.1126/science.8096089. [DOI] [PubMed] [Google Scholar]
  33. Reddy M. M., Winger E. E., Hargrove D., McHugh T., McKinley G. F., Grieco M. H. An improved method for monitoring efficacy of anti-retroviral therapy in HIV-infected individuals: a highly sensitive HIV p24 antigen assay. J Clin Lab Anal. 1992;6(3):125–129. doi: 10.1002/jcla.1860060305. [DOI] [PubMed] [Google Scholar]
  34. Semple M., Loveday C., Weller I., Tedder R. Direct measurement of viraemia in patients infected with HIV-1 and its relationship to disease progression and zidovudine therapy. J Med Virol. 1991 Sep;35(1):38–45. doi: 10.1002/jmv.1890350109. [DOI] [PubMed] [Google Scholar]
  35. Tsoukas C. M., Bernard N. F. Markers predicting progression of human immunodeficiency virus-related disease. Clin Microbiol Rev. 1994 Jan;7(1):14–28. doi: 10.1128/cmr.7.1.14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Wei X., Ghosh S. K., Taylor M. E., Johnson V. A., Emini E. A., Deutsch P., Lifson J. D., Bonhoeffer S., Nowak M. A., Hahn B. H. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995 Jan 12;373(6510):117–122. doi: 10.1038/373117a0. [DOI] [PubMed] [Google Scholar]
  37. Winters M. A., Tan L. B., Katzenstein D. A., Merigan T. C. Biological variation and quality control of plasma human immunodeficiency virus type 1 RNA quantitation by reverse transcriptase polymerase chain reaction. J Clin Microbiol. 1993 Nov;31(11):2960–2966. doi: 10.1128/jcm.31.11.2960-2966.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. van Gemen B., Kievits T., Schukkink R., van Strijp D., Malek L. T., Sooknanan R., Huisman H. G., Lens P. Quantification of HIV-1 RNA in plasma using NASBA during HIV-1 primary infection. J Virol Methods. 1993 Jul;43(2):177–187. doi: 10.1016/0166-0934(93)90075-3. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES